Examining orexinergic modulation of the paraventricular nucleus of the thalamus as a novel therapeutic for PTSD and comorbid psychosis

检查丘脑室旁核的食欲素调节作为 PTSD 和共病精神病的新型治疗方法

基本信息

  • 批准号:
    10579193
  • 负责人:
  • 金额:
    $ 1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-01 至 2023-05-26
  • 项目状态:
    已结题

项目摘要

Project Abstract Post-traumatic stress disorder (PTSD) is a prevalent condition that afflicts approximately 8% of the United States population. In addition to core symptoms of the disorder, up to 64% of individuals diagnosed with PTSD experience symptoms of psychosis, such as hallucinations and delusions. Although the incidence of this comorbidity is high, treatment for PTSD and comorbid psychosis remains inadequate. However, recent work has demonstrated the antipsychotic potential of orexin receptor antagonists in a rodent model used to study PTSD. Selective and nonselective orexin receptor antagonists, when administered systemically, can alleviate psychosis-like neurophysiological and behavioral deficits in a rodent model used to study PTSD. Orexin receptors are expressed throughout the brain but the paraventricular nucleus of the thalamus (PVT) receives the highest concentration of orexin fibers, suggesting orexin receptor antagonists can significantly inhibit activity of the PVT. It has been shown that chemogenetic activation of projections from the PVT to the nucleus accumbens (NAc) increase dopamine neuron activity in the ventral tegmental area, which underlies psychosis-like behavior. Further, the PVT is a stress-sensitive region and discrete projections from the PVT to the NAc become activated following stressful events. Taken together, these data suggest that stress increases the activity of PVT NAc projections and this heightened activity results in an increase in downstream dopamine neuron activity. Orexin receptors are highly expressed within the PVT; therefore, it is further hypothesized that orexin receptor antagonists alleviate psychosis-like behavior by inhibiting the activity of PVT NAc projections following stress. In the current proposal two-day inescapable footshock will be used to induce stress-related pathophysiology in Sprague Dawley rats. Aim 1 will test the hypothesis that footshock stress-induced increases in the firing rate of PVT NAc projecting neurons are reversible by selective orexin receptor antagonists. Aim 2 will test the hypothesis that inhibition of PVT NAc projections will normalize stress-induced increases in dopamine neuron activity and reverse deficits in prepulse inhibition of startle. The proposed studies will examine the role of PVT NAc projections in mediating psychosis-like behavior and examine the direct effect of selective orexin receptor antagonists on PVT NAc projections, following stress. Ultimately this proposal aims to uncover novel therapeutic targets that will alleviate symptoms of psychosis associated with PTSD. My long-term goal is to become an independent neuroscientist that studies circuit-level alterations contributing to psychiatric disorders. The research plan described above will provide me with scientific training in techniques, such as fiber photometry and chemogenetics, that I will utilize throughout my career to examine and manipulate neuronal circuits. Further, I will present data gathered from these experiments at local and national conferences and enhance my science communication skills. This award will provide me with scientific and career development training that will prepare me for a productive postdoctoral fellowship and success as an independent researcher.
项目摘要

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hannah Elam其他文献

Hannah Elam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 1万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 1万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 1万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    8391749
  • 财政年份:
    2006
  • 资助金额:
    $ 1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了